Please join us September 17, 2019 at The Water’s Edge at Giovanni’s in Darien. James Baumgartner, Ph.D. , president of Panacea Life Sciences will be Separating Fact from Fiction regarding industrial Hemp.
Abstract - The 2018 farm bill has legalized products derived from the industrial hemp plant which has spawned a new industry expected to eclipse 25 billion dollars in United States retail sales by 2023. Because the industrial hemp plant, Cannabis sativa (L) has been kept in the dark due to prior DEA schedule 1 designation, there is much that the scientific and medical communities are just beginning to learn about the plant and its application to human and animal health. The industrial hemp plant, and one of its major cannabinoids Cannabidiol (CBD), may be one of the richest sources for new human health supplements discovered in our lifetime. CBD has been reported through anecdotal information to address over 100 human conditions ranging from acne to cancer. While the potential to develop novel medications, supplements and beauty products are immense, the regulations on how to commercialize products are emerging on a daily basis. In this discussion, we will provide an overview of the industrial hemp plant and cannabidiol, share information on preliminary research on cannabidiol and how this will have positive impacts for the personal care industry, as well as what is on the horizon with the next wave of cannabinoids.
Biography - James (Jamie) Baumgartner was appointed President of Panacea Life Sciences in November, 2017. Jamie has had a lifelong passion for bringing novel treatments to patients in need. Jamie holds a Bachelor of Science in Biochemistry from the UC, Davis and a Ph.D. in Biochemistry and Pharmacology from Washington State University. He is an innovative business leader who combines his acute business acumen with his broad scientific excellence. His expertise in drug discovery and development has led to him assisting over 700 biotechnology and pharmaceutical companies reach unparalleled levels of success, especially in the area of advancing projects to IND filing. He adds over 25 years of drug discovery experience to Panacea Life and reinforces the company’s commitment to its foundation in scientific research and development in the healthcare and biotech industries.